الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 139 |  |  |
| | | from | 139 | | |
Abstract
Hepatitis C virus (HCV) is one of the main causative agents of chronic viral hepatitis. Chronic hepatitis C can progress to cirrhosis and eventually to hepatocellular carcinoma over a period of 20 to 30 years.
Different mechanisms including immunological liver, direct cytotoxicity mediated by different viral product and inductions of oxidative stress have been suggested as playing a pathogenic role in this infection.
It has been suggested that HCV may cause oxidative stress in infected cell.
In our study:A total of 40 patients were enrolled, Patients aged range between 40 and 60 all are males divided in two groups:
Group I: 20 patients have been infected with HCV and have been treated with pegylated interferon and ribavin combination therapy but not responded to treatment after 12 weeks.
The patients after treatment still have high level of ALT, AST and positive PCR for HCV RNA
Group II: 20 patients with chronic hepatitis C infection was selected from patients who were anti- HCV positive for more than 6 months and were showing high levels of ALT and AST before treatment with pegylated interferon an ribavirin combination therapy and responded to treatment after 24 to 48 weeks by showing normal value of ALT, AST and negative PCR for HCV RNA.
Pegylated interferon α-2a and ribavirin combination therapy
The selected patients’ received interferon α-2a as vials each 1.2/vial containing 160 mg peg Hansenula-derived liquid interferon one vial by week.
The daily dose of ribavirin is 800 mg to 1200 mg according to body weight administrated orally in two divided doses.
Ribavirin Dose is taking for genotype 1, 4 according to body weight <75 kg 1000 mg and >75 kg 1200 mg
Patients are advised to take ribavirin with food because its absorption increases when taken with a meal our result showed that:
In groupI (non responder group)
Total antioxidants before treatment was 0.2±0.04mM/Land after treatment 0.2±0.05mM/L at P value 0.5 in which there is no significant decrease or increase in its value
MDA before treatment was 13.2±0.9n mol / L and after treatment was10.4±0.9 at P value 0.001 in which there is significant decrease in its value
SOD before treatment was 206.7±2.3 U/ml and after treatment was 205.7±2.6 U/ml at P value 0.2 in which there is no significant change in its value
CAT before treatment was 299.1±4.7 U/L and after treatment was 310.1±6.5 U/L with P value 0.001 in which there is significant increase in its value
GST before treatment was 197.9±3.8 U/L and after treatment was 166.6±11.1 U/L at P value 0.001 in which there is significant decrease in its value
IL-6 before treatment was 10.06±0.3 pg/mL and after treatment was 8.1±0.7 pg/mL at P value 0.001 in which there is significant decrease in its value
IL-28B before treatment was 11.9±0.5 pg/mL and after treatment was 12.05±0.4 pg/mL at P value 0.3 in which there is no significant change in its value
In group II (responder group)
Total antioxidants before treatment was 0.2±0.07mM/Landsignificantly decrease after treatment to 0.8±0.2mM/L at P value 0.001
MDA before treatment was 14.1±1.1n mol / L and after treatment was3.9±1.3at P value 0.001 in which there is significant decrease in its value
SOD before treatment was 204.2±2.6 U/ml andsignificantly increases after treatment to 326.3±15.6 U/ml at P value 0.001
CAT before treatment was 298.5±4.7 U/L and significantly increases after treatment to 519.9±19.3 U/L at P value 0.001
GST before treatment was 196.5±4.1 U/L and significantly increases after treatment to 100.3±12.03 U/L at P value 0.001
IL-6 before treatment was 9.7±0.5 pg/mL and significantly decrease after treatment to 5.6±0.7 pg/mL at P value 0.001
IL-28B before treatment was 12.02±0.5 pg/mL andsignificantly decrease after treatment to 6.2±0.5 pg/mL at P value 0.001
Also we find a strong correlation between duration of treatment by interferon and ribavirin combination therapy and (Total antioxidants, MDA, SOD, CAT, GST, IL-6 and IL-28B) among responder group in which there a positive correlation between duration of treatment and (total antioxidants, SOD and CAT) they increase with increasing duration of treatment while there is negative correlation between duration of treatment and (MDA, GST, IL-6 and IL-28B) they decrease with increasing duration of treatment